

FILED 2-102



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> :  A61K 31/70	A1	(11) International Publication Number: WO 92/03140  (43) International Publication Date: 5 March 1992 (05.03.92)
(21) International Application Number: PCT/US91/05721 (22) International Filing Date: 12 August 1991 (12.08.91) (30) Priority data: 567,018 14 August 1990 (14.08.90) US (60) Parent Application or Grant (63) Related by Continuation US 567,018 (CON) Filed on 14 August 1990 (14.08.90) (71)(72) Applicant and Inventor (for all designated States except US): HANDELMAN, Joseph, H. [US/US]; 26 West 61 Street, New York, NY 10023 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): SHANDER, Douglas [US/US]; 16112 Howard Landing Drive, Gaithersburg, MD 20878 (US). HARRINGTON, Eugene, F. [US/US]; 45 West Main Street, New Market, MD 21774 (US). AHLWALLA, Gurpreet, S. [US/US]; 8632 Stable View Court, Gaithersburg, MD 20879 (US).	(74) Agents: GALLOWAY, Peter, D. et al.; Ladas & Parry, 26 West 61 Street, New York, NY 10023 (US).  (81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MN, MR (OAPI patent), MW, NL, NL (European patent), NO, PL, RO, SD, SE, SE (European patent), SN (OAPI patent), SU*, TD (OAPI patent), TG (OAPI patent), US.  Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(54) Title: ENZYMIC ALTERATION OF HAIR GROWTH  (57) Abstract  The rate and character of mammalian hair growth is altered by topical application to the skin of a composition containing a dermatologically acceptable carrier and an inhibitor of S-adenosylmethionine decarboxylase with or without an ornithine decarboxylase inhibitor.		

\* See back of page

# + DESIGNATIONS OF "SU"

Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

## FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU <sup>+</sup>	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

WO 92/03140

PCT/US91/05721

- 1 -

ENZYMIC ALTERATION OF HAIR GROWTH

This invention relates to alteration in the rate and character of mammalian hair growth by topical application through the skin of compositions containing an inhibitor of the enzyme S-adenosylmethionine decarboxylase.

U.S. Patent No. 4,039,669 describes the topical use of 17-alpha-R-androst-4-en-17-beta-ol-3-one or esters thereof where the R is n-propyl or n-butyl for the control of dermatological systems associated with androgen-mediated conditions such as acne.

U.S. Patent No. 4,139,638 and 4,161,540 describe the use of certain 4'-substituted and 3', 4'-disubstituted anilides for the treatment of androgen dependent disease states such as female hirsutism and acne.

U.S. Patent No. 4,191,775 discloses that certain 3,4-disubstituted branched-chain fluorinated acylanilides may be used in the topical treatment of androgen-dependent disease conditions such as acne, female hirsutism, and seborrhea.

U.S. Patent No. 4,344,941, describes the topical use of certain androgenic 17-alpha-substituted steroids exemplified by 17-beta-hydroxy-1-alpha-methyl-17-alpha(1-methyl-2-propenyl)-5-alpha-androstan-3-one for the treatment of diseases such as acne, seborrhea, alopecia and female hirsutism.

U.S. Patent No. 4,367,227 describes a cosmetic composition for reducing sebum secretion from the skin

WO 92/03140

PCT/US91/05721

- 2 -

comprising alcoholic solutions of cyproterone acetate.

West German OLS 2,840,144 describes the use of a combination of progesterone with either cyproterone acetate or chlormadinone acetate in the topical

5 treatment of androgen induced hormonal disturbances such as alopecia, female hirsutism, and acne.

Japanese Kokai 58-57308 describes the restoration of hair to bald heads by the topical applications of oxidizing substances such as stabilized  
10 chlorine dioxide, potassium bromate, or ozone to suppress the enzymatic activity of the reductive enzyme 5-alpha-reductase.

→ The patent art discloses a number of ways of  
reducing the growth of human hair as opposed to its  
15 conventional removal by cutting, shaving, or  
depilation. One such method is described in U.S. Patent No. 3,426,137, which pertains to a process for inhibiting the growth of hair by the topical  
20 application to a depilated skin area of a composition containing a substituted benzophenone such as 2-amino-5-chloro-benzophenone. Examples in the patent illustrate the reduction of hair growth on the back area of rabbits and on the arm of a male human subject.

Another process for extending the duration of  
25 depilation is described in U.S. Patent No. 4,370,315. The process therein comprises the topical application of a composition containing a lipxygenase along with linoleic acid or derivative thereof. The patent describes the application of such composition to  
30 various body parts of female human subjects in the majority of which regrowth of hair was clearly perceptible only after six or more weeks.

In U.S. Patent No. 4,439,432 topical compositions containing progesterone are reported for  
35 use in treatment of progesterone deficiency and related conditions, including abnormal hair growth resulting from androgen excess. Further insights on this point

- 3 -

may be obtained from the related literature, among which mention may be made of Simpson et al. "The Effect of Topically Applied Progesterone on Sebum Excretion Rate," Br. J. Derm., Vol. 100, p. 687 (1979), in which  
5 progesterone was reported effective in reducing sebum excretion rates in females, but without effect in males. In Goos et al., "An Improved Method for Evaluating Antiandrogens," Arch. Dermatol. Res. Vol. 273, pp. 333-341 (1982), the effect of progesterone on inhibition of  
10 hair growth in intact males appears to be doubtful (p. 340, Table 3, Group VI vs. Group X). In Burdick et al., "The Topical Effect of the Antiandrogen Chlormadinone Acetate and Some of Its Chemical Modifications on the Hamster Costovertebral Organ,"  
15 "Br. J. Derm., Vol. 82, Supplement 6, p. 19 (1970), antiandrogens were either ineffective or of questionable effect in inhibiting flank organ function in normal intact male hamsters. Similarly, in Girard et al., "Inhibition of Testosterone Metabolism and Lipogenesis  
20 in Animal Sebaceous Glands by Progesterone," Arch. Dermatol. Res., Vol. 269, pp. 281-290 (1980), progesterone is found effective in the female but not in the male. In all of the above experiments topical antiandrogens were ineffective in males in inhibiting  
25 androgenic function. When the female and male responses were compared in both humans and hamsters, only females responded to topical treatment.

In U.S. Patent No. 4,269,831 a substantial reduction in hair growth of the hamster flank organ is  
30 among the effects reported from topical application of 17 $\beta$ -hydroxy-17 $\alpha$ -propylandroster-4-en-3-one. However reduction in the size of the flank organ is also described, leaving a smaller field on which the hair can grow. Therefore, the reduction in hair growth may be a  
35 consequence of a decrease in area of the flank organ rather than an alteration in the character of the hair.

U.S. Patent No. 4,885,289 describes altering

- 4 -

the rate and character hair growth by topical application of 5-alpha-reductase inhibitors and/or cytoplasmic androgen receptor binding agents, while U.S. Patent No. 4,720,489 describes the topical application of ornithine decarboxylase inhibitors for similar purposes, either alone or in combination with the materials of U.S. 4,885,289.

Although it has been theorized that a variety of enzymes are involved in the growth of the cells of human hair, the relationship between such enzymes and between the reactions which they control, as well as their effect upon each other has not been fully understood, as appears from Pegg, Cancer Research, Vol. 48, 759-774 (1988); Gupta et al., Molec. and Biochem. Parasitology, Vol. 23, 247-252 (1987); and Elo et al., Cancer Letters, Vol. 41, 21-30 (1988).

It has now been found that the rate and character of mammalian (including human) hair growth can be altered by topical application to the skin of a composition containing an inhibitor of S-adenosyl-methionine decarboxylase (SAMDC), and further that such an inhibitor can be applied in combination with an ornithine decarboxylase inhibitor to produce greater effects than either inhibitor alone. Compositions containing one or a combination of both inhibitors in any conventional nontoxic dermatologically acceptable carrier or vehicle can be used for application of the combination to the desired areas of the skin. Such compositions may contain 0.1 to 50%, based on the total weight, of an inhibitor of SAMDC, and from 0.1 to 20% of an ornithine decarboxylase inhibitor.

Among the known inhibitors of SAMDC are methylglyoxal bis(guanylhydrazone) (MGBG); diethylglyoxal bis(guanylhydrazone) (DEGBG); and 5'-deoxy-5'-[N-methyl-N-(2-[aminoxy]ethyl)] aminoadenosine (MAOEA).

Among the known ornithine decarboxylase (ODC)

WO 92/03140

PCT/US91/05721

- 5 -

inhibitors which can be used are those described in U.S. Patent Nos. 4,201,788; 4,413,141; 4,421,768; and 4,720,489; of these, the preferred ODC inhibitors are 2-(difluoromethyl)-ornithine (DFMO); alpha-ethynyl  
5 ornithine; 6-heptyne-2,5-diamine, and 2-methyl-6-heptyne-2,5-diamine. In choosing ODC inhibitors for use in the practice of this invention, it is important to avoid those known to have secondary pharmacological effects such as 5-hexyne-1,4-diamine, which is known to  
10 bring about increases in brain 4-aminobutyric acid levels by a transformation catalyzed by mitochondrial monoamine oxidase. To minimize the risk of alteration of other bodily functions through systemic action, it is preferred to apply the ODC inhibitors in compositions  
15 such that the level of application will range from about 1 to about 2000 micrograms of active material per square centimeter of skin; still more preferred is the application of about 50 to about 500 micrograms per square centimeter of skin.

20 The SAMDC inhibitor or inhibitors is also preferably applied so that the amount of active material is from about 1 to about 5000 micrograms per square centimeter of skin.

25 The relative proportions of SAMDC inhibitor and of ODC inhibitor in the compositions as applied to the skin is not critical and may be varied over a wide range; preferred are compositions in which the relative proportions range from 1:10 to 10:1 by weight.

30 The following specific examples are intended to illustrate the nature of the invention without acting as a limitation on its scope.

Example 1

A vehicle or carrier was prepared having the following composition:

35	<u>Component</u>	<u>Wt. Percent Concentration</u>
	Water	68%
	Ethanol	16%

- 6 -

Propylene Glycol	5%
Dipropylene Glycol	5%
Benzyl Alcohol	4%
Propylene Carbonate	2%

5 A series of compositions was prepared each containing a given concentration of specified inhibitor in the foregoing vehicle, as listed in Table 1 below.

Four groups (eight animals in each group) of male intact Golden Syrian hamsters were provided. These animals were considered acceptable models for human beard hair growth in that they display oval shaped flank organs, one on each side, each about 8mm in major diameter, which grow thick black and coarse hair similar to human beard hair. These organs produce hair in response to androgens in the hamster. The flank organs of each hamster were depilated by applying a thioglycolate-based chemical depilatory (Surgex), and to one organ of each animal was applied 10 $\mu$ L. of vehicle alone once a day, while to the other organ of each animal was applied an equal amount of vehicle containing inhibitor. After 14 such applications (Mon.- Fri.) over a period of 18 days, the flank organs were shaved and the amount of recovered hair (hair mass) from each was weighed. The extent of reduction in hair growth by the inhibitor was expressed as the percent decrease in hair mass on the organ treated with inhibitor as compared to the organ treated with vehicle alone. As a control, one group of eight animals had both flank organs of each animal treated with vehicle alone. The results were as shown in Table 1 below.

Table 1

Inhibitor	Flank Organ (mg $\pm$ SE) Treated	Hair Mass		Hair Growth Inhibition (%)
		Control		
5% MAOEA	2.03 $\pm$ .18	2.68 $\pm$ .13		29.4 $\pm$ 5.9
5% MGBG	1.54 $\pm$ .22	2.63.22		40.3 $\pm$ 7.4
5% DFMO	0.99 $\pm$ .08	2.89 $\pm$ .22		64.3 $\pm$ 3.7



- 7 -

5% MAOEA and 5% DFMO	0.76±.11	2.66±.18	70.9±4.8
None	3.04±.24	3.05±.20	0±.53

Example 2

5 The same procedure was followed as in  
Example 1 except that the vehicle used for the  
compositions consisted of water alone. The compositions  
used and the results obtained were as shown in Table 2  
below:

Table 2

	Inhibitor	Flank Organ (mg±SE) Treated	Hair Mass		Hair Growth Inhibition (%)
				Control	
15	2.5% DEGBG	2.62±.15	3.15±.17	15.9±5.2	
	5% DFMO	2.70±.22	3.37±.22	18.8±3.7	
	2.5% DEGBG and 5% DFMO	2.30±.26	2.91±.21	21.7±5.3	

Example 3

20 Compositions were prepared as described in  
Example 1 containing the inhibitors listed in Table 3.  
The same test procedure was followed except that the  
compositions were applied to the hamster flank organs  
every day for fifteen successive days, at which time  
hair mass was measured; the results were as follows:

Table 3

	Inhibitor	No Animals	Flank Organ (mg±SE) Treated	Hair Mass Control	Hair Growth Inhibition (%)
30	5% MGBG	6	0.56±.11	0.99±.13	42.3±8.2
	5% DFMO	7	0.49±.14	0.92±.13	44.4±18.2
	5% MGBG and 5% DFMO	8	0.16±.03	0.87±.08	80.7±3.2
	None	7	0.85±.13	0.91±.21	6.47±10.0

35 Similar results can be obtained with other  
inhibitors of SAMDC and of ODC.

- 8 -

C L A I M S

1. The process of reducing the rate and altering the character of mammalian hair growth which comprises the step of applying to the skin a composition containing an inhibitor of S-adenosylmethionine decarboxylase.
2. The process as claimed in claim 1, in which said composition contains in addition an ornithine decarboxylase inhibitor.
3. The process as claimed in claim 1 or 2, in which said inhibitor of S-adenosylmethionine decarboxylase is selected from the group consisting of methylglyoxal bis(guanylhydrazone), diethylglyoxal bis(guanylhydrazone), and 5'-deoxy-5'-[N-methyl-N-(2-[aminooxy]ethyl)] aminoadenosine.
4. The process as claimed in claim 2, in which said ornithine decarboxylase inhibitor is selected from the group consisting of 2-(difluoromethyl)-ornithine, alpha-ethynyl ornithine; 6-heptyne-2,5-diamine and 2-methyl-6-heptyne-2,5-diamine.
5. The process as claimed in claim 4, in which said inhibitor of S-adenosylmethionine decarboxylase is selected from the group consisting of methylglyoxal bis(guanylhydrazone), diethylglyoxal bis(guanylhydrazone), 5' and 5'-deoxy-5'-[N-methyl-N-(2-[aminooxy]ethyl)] aminoadenosine.
6. The process as claimed in any of claims 1, 2, 3, 4 or 5 in which the rate of applying is from 1 to 5000 micrograms of said inhibitor of S-adenosylmethionine decarboxylase per square centimeter of skin.
7. The process as claimed in any of claims 2, 4, or 5 in which the rate of applying is from 1 to 2000 micrograms of said ornithine decarboxylase inhibitor per square centimeter of skin.
8. The process as claimed in claim 7, in which the rate of applying said inhibitor of S-adenosylmethionine decarboxylase is from 1 to 5000 micrograms per square

WO 92/03140

PCT/US91/05721

- 9 -

centimeter of skin.

9. A topical composition for reducing the rate and altering the character of mammalian hair growth comprising a non-toxic dermatologically acceptable carrier and from 0.1 to 50%, based on the total weight of said composition, of an inhibitor of S-adenosylmethionine decarboxylase and from 0.1 to 20% of an ornithine decarboxylase inhibitor.

10. A composition as claimed in claim 9, in which said inhibitor of S-adenosylmethionine decarboxylase is selected from the group consisting of methylglyoxal bis(guanyldrazone), diethylglyoxal bis(guanyldrazone), and 5'-deoxy-5'-[N-methyl-N-(2-[aminooxy]ethyl)] aminoadenosine.

11. A composition as claimed in claim 9, in which said ornithine decarboxylase inhibitor is selected from the group consisting of 2-(difluoromethyl)-ornithine, alpha-ethynyl ornithine; 6-heptyne-2,5-diamine and 2-methyl-6-heptyne-2,5-diamine.

---

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/05721

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC (5): A61K 31/70		
U.S.C1.: 514/46		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched ?		
Classification System	Classification Symbols	
U.S.C1.	514/46	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *		
CAS, DIALOG SEARCH TERMS: SAMDC INHIBITOR, ODC INHIBITOR, MGBG, DEGBG, MAOEA, ORNITHINE, DIAMINE		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT *</b>		
Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages **	Relevant to Claim No. **
Y	US, A, 4,720,499 (SHANDER) 19 January 1988 See entire document.	1-11
Y	Arch Toxicol, 59 (SUPPL) (9): 455. "Variable Effects of Irritants (Methylmethacrylate, Tophenyls, Dithranol, and Methylglyoxal -bis- Guanylhydrazone) on the Fine Structure of the Epidermis." 1986. (L. Kanerva et al.) See entire document.	1-11
Y	Acta Dermatovenere 62(3):221-224. "Methylglyoxal Bis (guanylhydrazone) and a-difluoro-methylornithine - induced Polyamine Deprivation in in Psoriatic Lesions". 1982 (M. Kousa et al.) See entire document.	1-11
Y	J. Invest, Dermatol 85(6): 518-521. "Regulation of Epidermal Proliferation in Mouse Epidermis by Combination of Difluoromethyl Ornithine (DFMO) and Methylglyoxal bis (guanylhydrazone) (MGBG)". 1985. (Abstract 7/5/9). (J.L. McCullough et al.) See entire document.	1-11
<p>* Special categories of cited documents: **</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
14 January 1992		03 FEB 1992
International Searching Authority		Signature of Authorized Officer
ISA/US		NGUYEN NGOC-BH Fr-Diane Gardner INTERNATIONAL DIVISION

